MDXG - MIMEDX GROUP, INC.
IEX Last Trade
9.13
2.950 32.311%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$6.18
2.95
47.73%
Fundamental analysis
54%
Profitability
66%
Dept financing
11%
Liquidity
50%
Performance
54%
Performance
5 Days
0.33%
1 Month
0.44%
3 Months
55.80%
6 Months
34.46%
1 Year
2.58%
2 Year
235.66%
Key data
Stock price
$9.13
DAY RANGE
$6.18 - $9.27
52 WEEK RANGE
$5.63 - $10.14
52 WEEK CHANGE
$1.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/28/2024
Company detail
CEO: K. Todd Newton
Region: US
Website: mimedx.com
Employees: 870
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mimedx.com
Employees: 870
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors.
Recent news